NDT Pharmaceuticals Showcases Strategic Value of Good Salt(TM) Life Acquisition with Expanded Relationship with Norwegian Cruise Line

October 21, 2025 8:30 AM

NDT Pharmaceuticals Inc. (OTC PINK:NDTP), a company focused on advancing innovative consumer health and wellness solutions, today announced a major post-acquisition milestone with the expanded relationship between its subsidiary, Good Salt™ Life, Inc., and Norwegian Cruise Line (NCL).Following NDT Pharmaceuticals' acquisition of Good Salt Life on September 5, 2025, the subsidiary has deepened its long-standing relationship with NCL, which has...

Read more

Alligator Bioscience Granted US Patent Covering ATOR-4066 Bispecific Antibody

October 21, 2025 4:45 AM

Alligator Bioscience (Nasdaq Stockholm: ATORX)(STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced that the United States Patent and Trademark Office (USPTO) has granted US Patent No. 12,448,465, covering the composition of matter of ATOR-4066, the company's bispecific antibody targeting CD40 and CEACAM5. The patent will formally issue on 21 October 2025.The granted patent...

Read more

Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors

October 20, 2025 2:50 AM

Transgene (Euronext Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class antibodies for cancer immunotherapy, are jointly presented a poster at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting on...

Read more

Updated BEXMAB Phase I/II Data Presented at ESMO 2025 Shows Further Improvement, Strengthening the Clinical Profile of Bexmarilimab in Treatment-Naïve HR-MDS Patients

October 20, 2025 2:15 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients with an 85% ORR and a 45% CR rate, bolstered by pharmacodynamic insightsNew biomarker data reveals strong correlation between target engagement and clinical response with 100% ORR in treatment-naïve, low blast count (Key...

Read more

Next Gen Diagnostics Showcases Low-Cost, Automated WGS-Based Transmission Detection Service at ID Week

October 16, 2025 11:00 AM

Next Gen Diagnostics (NGD) will showcase its new NGD System at ID Week 2025, in Atlanta October 19-22. Attendees can visit Booth #712 to see how NGD's end-to-end, on-premise service enables hospitals to detect and stop infection transmission in real time.The NGD System integrates complete robotic sample preparation, sequencing, bioinformatics and HIPAA-compliant root cause determination, all in a streamlined workflow. Come to the booth to learn...

Read more

Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum Proteomics

October 16, 2025 9:45 AM

In a major advancement for Duchenne muscular dystrophy (DMD) research and patient care, a multi-institutional team led by investigators from Leiden University Medical Center, the University of Florida and BioSymetrics Inc (a subsidiary of Lunai Bioworks Inc.; NASDAQ:LNAI) has identified serum proteins that can serve as prognostic biomarkers in DMD. The study, published today in Nature Communications and supported by Parent Project Muscular...

Read more

Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 16, 2025 9:15 AM

Lunai Bioworks, Inc. (Nasdaq:LNAI), today announced that it has regained compliance with Nasdaq's minimum bid price requirement.On April 14, 2025, Nasdaq Staff notified the Company that its common stock had failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days, as required by Listing Rule 5550(a)(2). However, Staff has since determined that for the 11 consecutive business days from September 30, 2025...

Read more

Repair Biotechnologies Announces Appointment of Noted Endocrinologist Prof. Frederick J. Raal to Scientific Advisory Board

October 16, 2025 9:00 AM

Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com/), a biotechnology company developing first-in-class therapies capable of rapidly reducing and stabilizing atherosclerotic plaque, today announced the appointment of Prof. Frederick J. Raal as a scientific advisor."We are pleased to welcome Prof. Frederick J. Raal, a noted endocrinologist and specialist in the study and treatment of familial hypercholesterolemia, to our...

Read more

Invitation to Alligator Bioscience's Earnings Call on 23 October 2025

October 16, 2025 3:00 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX) ), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, will publish its interim report for the third quarter 2025 on Thursday, 23 October 2025, at 8:00 a.m. CEST.On the same day, Alligator will host a webinar and conference call for investors, analysts, and media at 3:00 p.m. CEST / 9:00 a.m. EDT, where CEO Søren Bregenholt and CFO Johan Giléus...

Read more

Owkin Launches K Pro: The First Agentic AI Co-Pilot for Biopharma Powered by Biological Reasoning Models

October 16, 2025 1:00 AM

Owkin today announces the launch of K Pro, its co-pilot bringing advanced agentic AI to biomedical research and drug development. K Pro helps pharmaceutical companies and biotechs make smarter decisions across the discovery and development pipeline, increase clinical success rates, and deliver decision-grade, data-driven biological insights fast enough to change program trajectories.Built on a decade of Owkin's AI innovation and in close...

Read more

Next Gen Diagnostics Expands U.S. Operations With New Lab in Kendall Square

October 14, 2025 4:00 PM

Next Gen Diagnostics (NGD), a biotechnology company delivering automated whole genome sequencing and bioinformatics to track infection transmission in real time, today announced the relocation of its laboratory to Kendall Square in Cambridge, Massachusetts.The new space, located at the center of one of the world's most dynamic life sciences hubs, will enable NGD to expand its R&D capabilities, strengthen collaborations with academic and industry...

Read more

Imagene AI Launches the Oncology Intelligence (OI) Suite Discovery Program at Oracle AI World

October 14, 2025 11:00 AM

Imagene AI, a pioneer in multimodal foundation models for precision oncology, announced today the launch of the OI Suite Discovery Program at Oracle AI World. The program provides complimentary access to OI Suite for researchers in biopharma and academic centers, enabling biomarker discovery and predictive modeling in a secure, no-code environment where researchers can explore, refine, and validate hypotheses, accelerating both the quality and...

Read more

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

October 14, 2025 9:00 AM

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced the expansion of its ongoing Phase 2 CALMA clinical trial evaluating investigational drug candidate IGC-AD1 for agitation in Alzheimer's disease. The trial has officially opened a new site at the University of South Florida's Department of...

Read more

NAYA Announces Partnership with Alpha Nuclide to Support Clinical Development in China for Its GPC3-Targeting Astatine-211 Alpha Therapy for HCC

October 13, 2025 9:35 AM

MIAMI, FL and JIAXING, CHINA / ACCESS Newswire / October 13, 2025 / NAYA Therapeutics, a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer therapies through the development of Astatine-211 (²¹¹At) targeted alpha therapies and natural killer (NK) cell engaging bifunctional antibodies today announced it has entered into a research & manufacturing partnership agreement with Alpha Nuclide, a...

Read more

Baptist Hospital Enhances Patient Safety and Air Quality with Good Salt(TM) Life's ByoCart(TM) Disinfection System

October 13, 2025 8:30 AM

NDT Pharmaceuticals Inc. (OTC PINK:NDTP), a leader in health and wellness solutions, today announced that its wholly owned subsidiary, Good Salt™ Life, Inc., has deployed its advanced ByoCart™ Disinfection System at Baptist Hospital, the flagship facility of Baptist Health. The ByoCart system will enhance Baptist Hospital's infection prevention and environmental safety protocols by improving both surface disinfection and air quality throughout...

Read more

REACtiVe-2 Phase 1 Data Featuring Mitazalimab Demonstrate Immune Activation in Metastatic Pancreatic Cancer - To be Presented at ESMO 2025

October 13, 2025 3:00 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announces the upcoming presentation of data from the Phase 1 REACtiVe-2 trial (NCT05650918) at the ESMO Congress 2025, showcasing the immunologic and clinical effects of mitazalimab in combination with dendritic cell therapy in patients with metastatic pancreatic cancer.The...

Read more

Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025

October 13, 2025 2:55 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will jointly present a poster on translational data and updated clinical results from the Phase 1...

Read more

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

October 10, 2025 7:50 PM

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced that during its Annual Meeting of Stockholders scheduled for and convened on October 10, 2025 (the "Annual Meeting"), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on August 18, 2025, were...

Read more

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

October 10, 2025 9:30 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced the pricing of an underwritten offering of 735,000 shares of common stock at a price to the public of $6.12 per share, for gross proceeds of approximately $4.5 million, before deducting underwriting discounts and commissions and other...

Read more

Good Salt Life Expands EPA Registrations and Anticipates New Milestone

October 9, 2025 8:30 AM

Good Salt Life, Inc., a wholly owned subsidiary of NDT Pharmaceuticals Inc. (OTC:NDTP) ("NDTP" or the "Company"), today announced significant progress in its expanding portfolio of biosecurity solutions. The Company has submitted a "me-too" registration application to the U.S. Environmental Protection Agency (EPA) for its hypochlorous acid (HOCl) disinfectant, which, if approved, would expand the label to include an efficacy claim for...

Read more